An Introduction to Movement Disorders
Movement disorders encompass a range of conditions including ataxia, dystonia, essential tremor, multiple system atrophy, Parkinson’s disease (PD) and restless legs syndrome. The treatment landscape of PD has seen numerous developments, including the introduction of dopamine agonists and MAO-B inhibitors, along with device-assisted therapies that prove particularly useful in advanced-stage disease. The first-line treatment of ataxia with botulinum toxin is long established, but new preparations of the drug are likely to contribute to the future landscape.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Movement Disorders Content
Assessment and Treatment of Myoclonus: A Review
touchREVIEWS in Neurology 2022;18(1):38–41 DOI: https://doi.org/10.17925/USN.2022.18.1.38
Myoclonus is defined as a sudden, brief, lightning-like muscle contraction.1 It was first described by Friedreich in 1881 when he detailed sharp jerks involving the bulk of a full muscle without marked limb or joint movement and called it paramyoclonus multiplex.2 Myoclonus may be described as either positive myoclonus (increase in contraction activity) or negative myoclonus (inhibition […]
Emerging Therapies in Friedreich’s Ataxia: A Review
touchREVIEWS in Neurology. 2022;18(1):32–7 DOI: https://doi.org/10.17925/USN.2022.18.1.32
It has been nearly 160 years since Friedreich’s ataxia (FRDA) was clinically recognized and described1 and 25 years since the FXN gene was discovered.2 Despite this, there are still no approved therapies for FRDA. FRDA is an autosomal, recessively inherited, neurodegenerative disease that typically presents in childhood and results in progressive gait and limb ataxia, with the extraneural features […]
Francisco Cardoso: International Parkinson and Movement Disorder Society (MDS) – President update
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]
Donald Gilbert, AAN 2022: Ecopipam investigated for the treatment of children and adolescents with Tourette’s syndrome – Phase 2b results
Ecopipam is an investigational first-in-class drug being evaluated for the treatment of children and adolescents with Tourette’s syndrome. Prof. Donald Gilbert (Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA) discusses the randomised, double-blind, placebo-controlled phase 2b study investigating ecopipam. The abstract entitled ‘Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, […]
Davide Martino, AAN 2022: Functional neurological symptoms in the time of COVID-19 – Learning from tic-like behaviours
Functional neurological symptoms have been observed in young people globally during the COVID-19 pandemic, presenting with rapid onset of complex motor and vocal tic-like behaviours. Dr Davide Martino (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) discusses the rise in tic-like behaviour during the COVID-19 pandemic and what registry studies taught us about interventions of […]
Angelo Antonini, AD/PD 2022: Key clinical highlights in movement disorders and Parkinson’s disease
Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses the key clinical highlights and hot topics in movement disorders and Parkinson’s disease. Questions: What are the key clinical highlights from the past year in the field of movement disorders and Parkinson’s disease? Disclosures: Prof. Angelo Antonini is a consultant for AbbVie, Bial, […]
Angelo Antonini, AD/PD 2022: α-Synuclein seeding activity in gastrointestinal biopsies of Parkinson’s disease patients
Gastrointestinal dysfunctions represent one of the main non-motor symptoms in Parksinon’s disease (PD). Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses a study that investigated α-Synuclein seeding activity in stomach-duodenum biopsies of PD patients by real-time quaking induced conversion (RT-QuIC) assay. The results suggest a deeper investigation in detection of α-Synuclein […]
Giuseppe Lauria Pinter, WCN 2021: The Unfolded Protein Response in ALS: Results of a Phase 2 Trial
touchNEUROLOGY met up with Prof. Giuseppe Lauria Pinter (University of Milan, Milan, Italy) to discuss the efficacy and outcome measures of a phase 2 study investigating guanabenz for the treatment of amyotrophic lateral sclerosis. The abstract entitled: ‘The unfolded protein response in Amyotrophic lateral sclerosis: Results of a Phase 2 Trial’ was presented at the […]
EAN 2020 – Time for Action. Predict. Prevent. Repair.
EAN President, Prof. Claudio Bassetti invites you to participate in the EAN 2020 congress. You can register for the virtual congress free-of-charge here. It’s a fantastic opportunity for everyone in the neurology community to benefit from the possibility of education, scientific news and best practice exchange from the comfort of home. Be sure to visit our EAN […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!